К. О. Шатский The aim of the study was to carry out a comparative evaluation of the therapeutic potency of Estrophantine ® , a drug of the highly active synthetic analog of prostaglandin F 2 alpha (PgF 2α ) cloprostenol, when goats with hydrometer were twice injected intramuscularly with a 10-day interval in a dose of 0.5 and 1.0 ml, respectively. The objects of the study were breeding goats of breeding age (n=6) and lactating goats (n=37) of the Zaanen breed diagnosed with false pregnancy during screening ultrasound examination. The animals were divided into two experimental groups according to the analogy principle. The animals in the first experimental group (n=21) were twice injected intramuscularly with a 10-day interval in the dose of 0.5 ml (125 μg cloprostenol), and those in the second group (n=22) were also twice injected intramuscularly with with a 10-day interval, but in the dose of 1.0 ml (250 μg cloprostenol). The results of the study showed high therapeutic potency of Estrophantine® when goats with hydrometer were twice injected intramuscularly with with a 10-day interval in the dose of 1.0 ml. After the first dose of the preparation complete expulsion of intrauterine fluid was noted in 81.82% of goats with hydrometer. The effectiveness of the method for a complete course of treatment was 100% according to the percentage of cured animals, and 86.36% and 77.27% according to the frequency of renewal of sexual cycling and pregnancy rate, respectively. None of the 5 (22.73%) goats found to be infertile registered a relapse of hydrometra after treatment. An Estrofantin ® dose of 0.5 ml (125 μg cloprostenol) was found to be inadequate for treatment of goats with hydrometra. After the first dose, complete expulsion of intrauterine fluid was noted in only 52.38% of animals. When Estrophantine ® is used at the lowest therapeutic dose (125 μg cloprostenol) the effectiveness of prostaglandin therapy over a full course of treatment is reduced by 4.76% in the proportion of cured animals, by 10.17% in the renewal of sexual cycling and by 15.37% in pregnancy rate. At the same time, the risk of relapse is 5%.
Научная статья 
лечение